z-logo
open-access-imgOpen Access
When Can We Stop Using Oral Poliovirus Vaccine?
Author(s) -
Harry F. Hull,
Philip D. Minor
Publication year - 2005
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/498171
Subject(s) - attenuated vaccine , virology , poliovirus , poliomyelitis , inactivated poliovirus vaccine , medicine , population , herd immunity , immunity , vaccination , virus , biology , environmental health , immunology , virulence , immune system , biochemistry , gene
In the years before the introduction of live, attenuated oral poliovims vaccine (OPV), there was a vigorous debate between advocates of killed and live vaccines. Proponents of live vaccine took the position that OPV would produce immunity more similar to that produced by wild viruses, providing superior individual and population protection. Proponents of inactivated poliovims vaccine (IPV) felt that there was a risk that attenuated viruses would regain their virulence and that person-to-person spread could permit continuous circulation of vaccine virus. On the basis of 50 years of experience with Salk' s killed poliovirus vaccine and MO years of experience with Sabin' s live, attenuated OPV, who was right? As is so often the case, both sides were. The first killed vaccine significantly reduced, but did not eliminate, polio. Mass campaigns with 3 monovalent OPVs brought the number of polio cases close to 0 in the United States. Although monovalent OPVs proved impractical for routine use, high coverage with trivalent OPV eliminated the disease from the United States; the last case caused by wild virus occurred

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom